drugset / Trial / NCT05410730
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
NaSingle-groupOpen-labelTreatment
Summary
The study is to evaluate the safety and tolerability of SHR-1501 alone or in combination with BCG or SHR-1316 in the patients with NMIBC, and to determine the RP2D of SHR-1501 in combination with BCG or SHR-1316. To evaluate the preliminary efficacy of SHR-1501 alone or in combination with BCG or SHR-1316 in the treatment of NMIBC.
Timeline
- Start
- 2022-11-23
- Primary completion
- 2025-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-1501 | Unknown | — | — |